Hossam Tashkandi, Ph.D.
About Hossam Tashkandi, Ph.D.
Hossam Tashkandi, Ph.D., is a Scientist I in In Vivo Pharmacology at SalioGen Therapeutics, with a background in oncology and regenerative medicine. He has a strong academic foundation, having earned a Ph.D. in Pharmaceutical Sciences from the University of South Carolina, and has contributed to significant research projects, including securing a $1.8 million grant.
Current Role at SalioGen Therapeutics
Hossam Tashkandi serves as Scientist I in In Vivo Pharmacology at SalioGen Therapeutics, a position he has held since 2022. In this role, he focuses on pharmacological studies that involve in vivo models, contributing to the development of therapeutics. His work is integral to advancing the company's research initiatives.
Previous Experience at University of South Carolina
Before joining SalioGen Therapeutics, Hossam Tashkandi worked at the University of South Carolina as a Postdoctoral Researcher from 2012 to 2021. During his nine years there, he engaged in significant research projects in oncology and regenerative medicine, contributing to the academic community through multiple publications.
Research Contributions and Publications
Hossam Tashkandi has authored three first-author and two middle-author publications in the fields of oncology and regenerative medicine. His research has provided valuable insights and data, including key contributions that helped secure a $1.8 million grant for a five-year research project.
Educational Background in Pharmaceutical Sciences
Hossam Tashkandi earned his Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences from the University of South Carolina, completing his studies from 2014 to 2020. He also holds a Master of Science (M.S.) in Biology/Biological Sciences, General, obtained from 2012 to 2014, and a Bachelor of Science (B.S.) in Biology, General, completed from 2007 to 2019.
Volunteer Work with Skype A Scientist
In addition to his scientific roles, Hossam Tashkandi has volunteered as a Scientist with Skype A Scientist since 2019. This initiative allows him to engage with the public and share his scientific knowledge, fostering interest in science and education.